A 16-week randomized placebo-controlled trial investigating the effects of omega-3 polyunsaturated fatty acid treatment on white matter microstructure in recent-onset psychosis patients concurrently treated with risperidone.
A 16-week randomized placebo-controlled trial investigating the effects of omega-3 polyunsaturated fatty acid treatment on white matter microstructure in recent-onset psychosis patients concurrently treated with risperidone.
复制标题
一项为期16周的随机安慰剂对照试验，调查了omega-3多不饱和脂肪酸治疗对白质微观结构的影响，在最近发作的精神病患者中，同时用利培酮治疗。
DOI：
10.1016/j.pscychresns.2020.111219
复制
发表时间：
2021-01-30
期刊：
影响因子：
--
通讯作者：
Szeszko PR
中科院分区：
文献类型：
--
作者：
Lyall AE;Nägele FL;Pasternak O;Gallego JA;Malhotra AK;McNamara RK;Kubicki M;Peters BD;Robinson DG;Szeszko PR
我们在一项双盲安慰剂对照随机临床试验中，研究了鱼油 (FO)（一种丰富的 omega-3 多不饱和脂肪酸 (n-3 PUFA) 来源）治疗对 37 名接受利培酮治疗的新发精神病患者白质的影响。患者在基线时接受扫描，并随机分配接受为期 16 周的利培酮 + FO 或利培酮 + 安慰剂治疗。 18 名患者接受了随访 MRI（FO，n=10/安慰剂，n=8）。在两个时间点获得n-3 PUFA二十碳五烯酸（EPA）、二十二碳六烯酸（DHA）和二十二碳五烯酸（DPA）的红细胞水平。我们采用代表细胞外自由水分数（FW）和组织分数各向异性（FA-t）的自由水成像指标。使用基于区域的空间统计和基于非参数排列的测试以及族误差校正进行分析。所有患者基线时 FA-t 与 DHA 和 DPA 均呈显着正相关。用利培酮+安慰剂治疗的患者表现出FA-t减少和FW增加，而用利培酮+FO治疗的患者FW没有显着变化，并且FA-t减少很大程度上减弱。 DPA 和 DHA 与基线 FA-t 的相关性支持 n-3 PUFA 摄入或生物合成与精神病白质异常相关的假设。辅助 FO 治疗可以部分减轻利培酮治疗后新发精神病患者观察到的白质改变。
We examined the impact of treatment with fish oil (FO), a rich source of omega-3 polyunsaturated fatty acids (n-3 PUFA), on white matter in 37 recent-onset psychosis patients receiving risperidone in a double-blind placebo-controlled randomized clinical trial. Patients were scanned at baseline and randomly assigned to receive 16-weeks of treatment with risperidone+FO or risperidone+placebo. Eighteen patients received follow-up MRIs (FO,n=10/Placebo,n=8). Erythrocyte levels of n-3 PUFAs eicosapentaenoic acid(EPA), docosahexaenoic acid(DHA), and docosapentaenoic acid(DPA) were obtained at both time points. We employed Free Water Imaging metrics representing the extracellular free water fraction(FW) and fractional anisotropy of the tissue(FA-t). Analyses were conducted using Tract-Based-Spatial-Statistics and nonparametric permutation-based tests with family-wise error correction. There were significant positive correlations of FA-t with DHA and DPA among all patients at baseline. Patients treated with risperidone+placebo demonstrated reductions in FA-t and increases in FW, whereas patients treated with risperidone+FO exhibited no significant changes in FW and FA-t reductions were largely attenuated. The correlations of DPA and DHA with baseline FA-t support the hypothesis that n-3 PUFA intake or biosynthesis are associated with white matter abnormalities in psychosis. Adjuvant FO treatment may partially mitigate against white matter alterations observed in recent-onset psychosis patients following risperidone treatment.
登录
查看更多内容
影响因子：
11
作者：
Lyall AE;Pasternak O;Robinson DG;Newell D;Trampush JW;Gallego JA;Fava M;Malhotra AK;Karlsgodt KH;Kubicki M;Szeszko PR
通讯作者：
Szeszko PR
影响因子：
11
作者：
Kelly S;Jahanshad N;Zalesky A;Kochunov P;Agartz I;Alloza C;Andreassen OA;Arango C;Banaj N;Bouix S;Bousman CA;Brouwer RM;Bruggemann J;Bustillo J;Cahn W;Calhoun V;Cannon D;Carr V;Catts S;Chen J;Chen JX;Chen X;Chiapponi C;Cho KK;Ciullo V;Corvin AS;Crespo-Facorro B;Cropley V;De Rossi P;Diaz-Caneja CM;Dickie EW;Ehrlich S;Fan FM;Faskowitz J;Fatouros-Bergman H;Flyckt L;Ford JM;Fouche JP;Fukunaga M;Gill M;Glahn DC;Gollub R;Goudzwaard ED;Guo H;Gur RE;Gur RC;Gurholt TP;Hashimoto R;Hatton SN;Henskens FA;Hibar DP;Hickie IB;Hong LE;Horacek J;Howells FM;Hulshoff Pol HE;Hyde CL;Isaev D;Jablensky A;Jansen PR;Janssen J;Jönsson EG;Jung LA;Kahn RS;Kikinis Z;Liu K;Klauser P;Knöchel C;Kubicki M;Lagopoulos J;Langen C;Lawrie S;Lenroot RK;Lim KO;Lopez-Jaramillo C;Lyall A;Magnotta V;Mandl RCW;Mathalon DH;McCarley RW;McCarthy-Jones S;McDonald C;McEwen S;McIntosh A;Melicher T;Mesholam-Gately RI;Michie PT;Mowry B;Mueller BA;Newell DT;O'Donnell P;Oertel-Knöchel V;Oestreich L;Paciga SA;Pantelis C;Pasternak O;Pearlson G;Pellicano GR;Pereira A;Pineda Zapata J;Piras F;Potkin SG;Preda A;Rasser PE;Roalf DR;Roiz R;Roos A;Rotenberg D;Satterthwaite TD;Savadjiev P;Schall U;Scott RJ;Seal ML;Seidman LJ;Shannon Weickert C;Whelan CD;Shenton ME;Kwon JS;Spalletta G;Spaniel F;Sprooten E;Stäblein M;Stein DJ;Sundram S;Tan Y;Tan S;Tang S;Temmingh HS;Westlye LT;Tønnesen S;Tordesillas-Gutierrez D;Doan NT;Vaidya J;van Haren NEM;Vargas CD;Vecchio D;Velakoulis D;Voineskos A;Voyvodic JQ;Wang Z;Wan P;Wei D;Weickert TW;Whalley H;White T;Whitford TJ;Wojcik JD;Xiang H;Xie Z;Yamamori H;Yang F;Yao N;Zhang G;Zhao J;van Erp TGM;Turner J;Thompson PM;Donohoe G
通讯作者：
Donohoe G
DOI：
10.1093/brain/awt310
发表时间：
2014-01
期刊：
Brain : a journal of neurology
影响因子：
--
作者：
Reis Marques T;Taylor H;Chaddock C;Dell'acqua F;Handley R;Reinders AA;Mondelli V;Bonaccorso S;Diforti M;Simmons A;David AS;Murray RM;Pariante CM;Kapur S;Dazzan P
通讯作者：
Dazzan P
DOI：
10.1016/j.bpsc.2019.01.002
发表时间：
2019-05-01
影响因子：
5.9
作者：
Kraguljac, Nina Vanessa;Anthony, Thomas;Lahti, Adrienne Carol
通讯作者：
Lahti, Adrienne Carol
影响因子：
10.6
作者：
Konopaske, Glenn T.;Dorph-Petersen, Karl-Anton;Lewis, David A.
通讯作者：
Lewis, David A.